A webinar presented by the Global Liver Institute highlighted areas of improvement needed in research for liver cancer, but also left listeners with hope for future treatments focused on strengthening immunity.
People with signs of the most advanced liver disease should see a hepatologist, experts say, while primary care clinicians can effectively treat lower-risk cases.
In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line. Last month, the FDA rejected the lead NASH drug contender, obeticholic acid, due to concerns that its risks outweigh its benefits. This action leaves Madrigal Pharmaceuticals’
Global Liver Institute Convenes Largest Number of Community Events around the World in the 6 Years of International NASH DayWashington, D.C., June 08, 2023, a time where healthcare experts and community